🇺🇸 FDA
Patent

US 10035848

Antibody targeting cell surface deposited complement protein C3d and use thereof

granted A61KA61K2039/505A61P

Quick answer

US patent 10035848 (Antibody targeting cell surface deposited complement protein C3d and use thereof) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K2039/505, A61P, A61P35/02